Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Philip Zeitler"'
Autor:
Natalie J. Nokoff, Samantha Bothwell, John D. Rice, Melanie G. Cree, Megan M. Kelsey, Kerrie L. Moreau, Philip Zeitler, Kristen J. Nadeau
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 36, Iss , Pp 100356- (2024)
Background: 1.8% of youth identify as transgender; a growing proportion are transgender male (female sex, male gender identity). Many receive gonadotropin releasing hormone agonist (GnRHa) therapy to suppress endogenous puberty and/or will start test
Externí odkaz:
https://doaj.org/article/75027ed3284a4ebdb8f7bcec3b80040c
Autor:
Shanlee M Davis, Rhianna Urban, Angelo D’Alessandro, Julie A Reisz, Christine L Chan, Megan Kelsey, Susan Howell, Nicole Tartaglia, Philip Zeitler, Peter Baker II
Publikováno v:
Endocrine Connections, Vol 12, Iss 5, Pp 1-9 (2023)
Conditions related to cardiometabolic disease, including metabolic syndrome and type 2 diabetes, are common among men with Klinefelter syndrome (KS). The molecular mechanisms underlying this aberrant metabolism in KS are largely unknown, although the
Externí odkaz:
https://doaj.org/article/7715c9af0b594652bec767cf26bc0cfb
Autor:
Shanlee Davis, Mariah Brown, Susan Howell, Jennifer Janusz, Najiba Lahlou, Laura Pyle, Regina Reynolds, Rebecca Wilson, Philip Zeitler, Nicole Tartaglia
Publikováno v:
Genetics in Medicine Open, Vol 1, Iss 1, Pp 100182- (2023)
Externí odkaz:
https://doaj.org/article/1cd5a9948a1743d58d753eb6c58dd7f2
Autor:
Jadranka Popovic, Mitchell E. Geffner, Alan D. Rogol, Lawrence A. Silverman, Paul B. Kaplowitz, Nelly Mauras, Philip Zeitler, Erica A. Eugster, Karen O. Klein
Publikováno v:
Frontiers in Pediatrics, Vol 10 (2022)
Gonadotropin-releasing hormone agonists (GnRHa's) are the standard treatment for children with central precocious puberty (CPP). We aim to present data on available GnRHa options with an easy-to-review table and discuss factors that influence treatme
Externí odkaz:
https://doaj.org/article/5a6c026d6afd496abf8abf6dc6199d95
Autor:
Janine Higgins, Philip Zeitler, Kimberly L. Drews, Silva Arslanian, Kenneth Copeland, Robin Goland, Georgeanna Klingensmith, Terri H. Lipman, Sherida Tollefsen
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 29, Iss , Pp 100300- (2022)
Aim: ZnT8 autoantibody positivity (ZnT8+) is associated with risk for type 1 diabetes and with metabolic complications in adults. Our aim was to assess prevalence of ZnT8 + in the Treatment of T2D in Adolescents and Youth (TODAY) cohort and describe
Externí odkaz:
https://doaj.org/article/be161448c3c545e18b73387a0fb1a3a0
Autor:
Lori M Laffel, Thomas Danne, Georgeanna J Klingensmith, William V Tamborlane, Steven Willi, Philip Zeitler, Dietmar Neubacher, Jan Marquard, Tatiana Bardymova, Margarita Barrientos Perez, Kathleen Bethin, Petter Bjornstad, Irina Bondar, Mimi Chen, Jin-Ho Choi, Mark A Clements, Javier Ricardo Colomar, Mark Daniels, Chaicharn Deerochanawong, Vivek S Desai, Jean-Claude G Desmangles, Robert G Dillon, Naznin M Dixit, Hongwei Du, Rachel Edelen, Diego Espinoza Peralta, María Verónica Felipe Gacioppo, Tania Maria Bulcão Lousada Ferraz, Galina Galkina, Mary Patricia Gallagher, Minu George, Edgar Gonzalez, Michael Everett Gottschalk, Giancarlo Guido, Amir Ali Hassan, Eli Hershkovitz, Lina P Huerta-Saenz, Jin Soon Hwang, Jaime Orlando Ibarra Gomez, Lydia Irizarry Gonzalez, Nina Jain, David H Jelley, Ho-Seong Kim, Tatiana Kovalenko, Lori Michelle B Laffel, Steven B Leichter, Raphael Del Roio Liberatore Jr, Jane Lynch, Farid Hussain Mahmud, Oleg Arturovich Malievskiy, Andrew Muir, Bryce A Nelson, Luis Alejandro Nevarez Ruiz, Micah L Olson, Emilia Susana Pelayo Orozco, Valentina Peterkova, Fernando Ramón Ramírez Mendoza, Konda Mohan Reddy, Henry Rodriguez, Javier Andres Saenz, Julia Samoilova, Karl-Otfried Schwab, Sejal H Shah, Naim Shehadeh, Ashley H Shoemaker, Yulia Skorodok, Aleksandr Sobolev, Silvana Ernestina Solís, Shylaja Srinivasan, Eva Tsalikian, Farida Valeeva, Carl D Vance, Pedro A Velasquez-Mieyer, Rafael Margarito Violante Ortiz, Olga Votyakova, Haiyan Wei, Ruth S Weinstock, Mark D Wheeler, Brandy Alexandra Wicklow, Steven M Willi, Kupper A Wintergerst, Risa M Wolf, Jamie Ruth Wood, Chandan Yaliwal, Hernán Yupanqui Lozno
Publikováno v:
The Lancet Diabetes & Endocrinology. 11:169-181
Autor:
Philip Zeitler, Laure El Ghormli, Silva Arslanian, Sonia Caprio, Elvira Isganaitis, Megan K Kelsey, Ruth S Weinstock, Neil H White, Kimberly Drews
Publikováno v:
J Clin Endocrinol Metab
Objective We examined predictors of early and late loss of glycemic control in individuals with youth-onset type 2 diabetes, as well as predictors of short-term deterioration in youth from the Treatment Options for type 2 Diabetes in Adolescents and
Autor:
Silva A, Arslanian, Tamara, Hannon, Philip, Zeitler, Lily C, Chao, Claudia, Boucher-Berry, Margarita, Barrientos-Pérez, Elise, Bismuth, Sergio, Dib, Jang Ik, Cho, David, Cox, Chandan, Saha
Publikováno v:
The New England journal of medicine. 387(5)
The incidence of type 2 diabetes mellitus is increasing among youths. Once-weekly treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist, may have efficacy with regard to glycemic control in youths with type 2 diabetes.In a double-bli
Autor:
SILVA A. ARSLANIAN, JANG IK CHO, TAMARA S. HANNON, PHILIP ZEITLER, LILY CHAO, MARGARITA BARRIENTOS, CLAUDIA C. BOUCHER-BERRY, ELISE BISMUTH, SERGIO A. DIB, DAVID COX
Publikováno v:
Diabetes. 71
AWARD-PEDS was a Phase 3 trial to assess the efficacy and safety of dulaglutide (DU) , a once-weekly GLP-1 receptor agonist, in youth (10 to In conclusion, in youth with inadequately controlled T2D treated with or without metformin and/or basal insul
Autor:
LORI M. LAFFEL, THOMAS DANNE, WILLIAM V. TAMBORLANE, GEORGEANNA J. KLINGENSMITH, CHRISTY SCHROEDER, DIETMAR NEUBACHER, NIMA SOLEYMANLOU, JAN MARQUARD, PHILIP ZEITLER, STEVEN M. WILLI
Publikováno v:
Diabetes. 71
T2D in youth remains challenging to manage and there is need for an expanded treatment armamentarium. The DINAMO study was designed to overcome recruitment difficulties that plagued previous T2D studies in youth. Within 3 years, DINAMO enrolled 158 p